They're charging much more than the cost to develop the drug, because they need to pay for all of their failed attempts (and at this point, the only constraint is when the insurance companies will balk). And if they're able to charge this indefinitely, then they're effectively just extracting rent regardless of how much goes into further research (which you can say that they've earned the right to do this, but that's still what they're doing).
I'm certainly not saying they shouldn't be compensated, but taking issue with they way they're compensated. As I said, the problem is that it's an extreme gamble, and the only thing this is conducive to is business gamers and the overhead and blindspots they bring. Since the current reimbursement mechanism completely relies on the utterly artificial construction of the patent system, it's reasonable to believe that the entire model could be redesigned.